

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Miller Michael Francis</u> _____ (Last) (First) (Middle) <u>C/O QUANTERIX CORPORATION</u> <u>900 MIDDLESEX TURNPIKE</u> _____ (Street) <u>BILLERICA MA 01821</u> _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/23/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>Quanterix Corp [ QTRX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Operating Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	30,262	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Performance Stock Unit	(1)	12/31/2026	Common Stock	74,905	0.00	D	
Restricted Stock Unit	(2)	(2)	Common Stock	99	0.00	D	
Restricted Stock Unit	(3)	(3)	Common Stock	809	0.00	D	
Restricted Stock Unit	(4)	(4)	Common Stock	1,003	0.00	D	
Restricted Stock Unit	(5)	(5)	Common Stock	30,027	0.00	D	
Restricted Stock Unit	(6)	(6)	Common Stock	10,061	0.00	D	
Restricted Stock Unit	(7)	(7)	Common Stock	3,251	0.00	D	
Restricted Stock Unit	(8)	(8)	Common Stock	1,797	0.00	D	
Restricted Stock Unit	(9)	(9)	Common Stock	74,905	0.00	D	
Stock Options (Right to buy)	(10)	07/28/2031	Common Stock	11,820	54.04	D	
Stock Options (Right to buy)	(11)	04/07/2032	Common Stock	10,543	29.62	D	
Stock Options (Right to buy)	(12)	02/02/2034	Common Stock	21,852	23.1	D	
Stock Options (Right to buy)	(13)	05/21/2034	Common Stock	60,123	16.78	D	
Stock Options (Right to buy)	(14)	02/06/2033	Common Stock	9,168	14.89	D	
Stock Options (Right to buy)	(15)	03/15/2033	Common Stock	15,320	11.89	D	
Stock Options (Right to buy)	(16)	09/23/2032	Common Stock	14,649	9.67	D	
Stock Options (Right to buy)	(17)	02/04/2035	Common Stock	131,147	8.43	D	

Explanation of Responses:

1. On February 15, 2026, the reporting person was granted 74,905 Performance Stock Units, with each PSU award to vest (subject to the employee's continued service to the Company on the applicable vesting dates) according to the schedule and conditions set forth in the executive long-term incentive plan contained in the Company's 2026 Employee Equity Guidelines. After the award's performance conditions are satisfied, the PSUs will vest in four equal annual installments on each of the first four anniversaries of the grant date
2. On April 7, 2022, the reporting person was granted 4,518 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.
3. On September 23, 2022, the reporting person was granted 6,278 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.
4. On February 6, 2023, the reporting person was granted 3,929 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.
5. On February 4, 2025, the reporting person was granted 40,036 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.
6. On May 21, 2024, the reporting person was granted 17,878 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.
7. On February 2, 2024, the reporting person was granted 6,494 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.
8. On March 15, 2023, the reporting person was granted 6,566 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.
9. On February 15, 2026, the reporting person was granted 74,905 restricted stock units, vesting 25% per year for four years.
10. On July 28, 2021, the reporting person was granted 11,820 stock options, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.
11. On April 7, 2022, the reporting person was granted 10,543 stock options, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.
12. On February 2, 2024, the reporting person was granted 21,852 stock options, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.
13. On May 21, 2024, the reporting person was granted 60,123 stock options, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.
14. On February 6, 2023, the reporting person was granted 9,168 stock options, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.
15. On March 15, 2023, the reporting person was granted 15,320 stock options, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.
16. On September 23, 2022, the reporting person was granted 14,649 stock options, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.
17. On February 4, 2025, the reporting person was granted 131,147 stock options, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the final day of each month thereafter.

**Remarks:**

/s/ Bonnie McManus,  
Attorney-in-Fact

03/05/2026

\*\* Signature of Reporting  
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of Daniel Char, Michael Lanieri, Bonnie McManus, and Meghan Shevlin as the undersigned's true and lawful attorney-in-fact to:

execute for and on behalf of the undersigned, in the undersigned's capacity as a beneficial owner of Quanterix Corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder and Schedules 13D and 13G in accordance with Section 13 of the Securities Exchange Act of 1934 and the rules thereunder;

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedules 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the "SEC") and any securities exchange or similar authority; and

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned also ratifies hereby any action previously taken by each attorney-in-fact that would have been authorized by this power of attorney if it had been in effect at the time such action was taken. The undersigned acknowledges that each foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 and Schedules 13D and 13G with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 17th day of February 2026.

/s/ Michael F. Miller name: Michael Miller